Elevated serum levels of soluble CX3CL1 in patients with microscopic polyangiitis

Clinical and Experimental Rheumatology

Volumn 27, Issue 1, 2009, Pages 72-78

  Matsunawa, Mizuho ^a   Odai, Tsuyoshi ^a   Wakabayashi, Kuninobu ^a   Isozaki, Takeo ^a   Yajima, Nobuyuki ^a   Miwa, Yusuke ^a   Nohtomi, Kyoko ^a   Takeuchi, Hiroko ^a   Kasama, Tsuyoshi ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemokine; CX3CL1; Cytokine; Microscopic polyangiitis

Indexed keywords

FRACTALKINE;

ADULT; AGED; AORTA ARCH SYNDROME; ARTICLE; BLOOD SAMPLING; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GIANT CELL ARTERITIS; HUMAN; HUMAN TISSUE; MALE; MICROSCOPIC POLYANGIITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; VASCULITIS;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOKINE CX3CL1; COHORT STUDIES; FLOW CYTOMETRY; GIANT CELL ARTERITIS; HUMANS; MALE; MICROVESSELS; MIDDLE AGED; TAKAYASU ARTERITIS; VASCULITIS;

EID: 63049133643     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. BUCKLEY CD, RAINGER GE, NASH GB RAZA K: Endothelial cells, fibroblasts and vasculitis. Rheumatology (Oxford) 2005; 44: 860-3.
2. KANEIDER NC, LEGER AJ, KULIOPULOS A: Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions. FEBS J 2006; 273: 4416-24.
3. LAMPRECHT P, GROSS WL: Current knowledge on cellular interactions in the WG-granuloma. Clin Exp Rheumatol 2007; 25: S49-51.
4. BNZAN JF, BACON KB, HARDIMAN G et al.: A new class of membrane-bound chemokine with a CX3C motif. Nature 1997; 385: 640-4.
5. PAN Y, LLOYD C, ZHOU H et al.: Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 1997; 387: 611-7.
6. IMAI T, HIESHIMA K, HASKELL C et al.: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997; 91: 521-30.
7. UMEHARA H, BLOOM E, OKAZAKI T, DOMAE N, IMAI T: Fractalkine and vascular injury. Trends Immunol 2001; 22: 602-7.
8. MATSUNAWA M, ISOZAKI T, ODAI T et al.: Increased serum levels of soluble fractalkine (CX3CL1) correlate with disease activity in rheumatoid vasculitis. Arthritis Rheum 2006; 54: 3408-16.
9. SORENSEN SF, SLOT O, TVEDE N, PETERSEN J: A prospective study of vasculitis patients collected in a five year period: Evaluation of the Chapel Hill nomenclature. Ann Rheum Dis 2000; 59: 478-82.
10. JENNETTE JC, FALK RJ, ANDRASSY K et al.: Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-92.
11. HUNDER GG, BLOCH DA, MICHEL BA et al.: The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-8.
12. AREND WP, MICHEL BA, BLOCH DA et al.: The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33: 1129-34.
13. LUQMANI RA, BACON PA, MOOTS RJ et al.: Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994; 87: 671-8.
14. YAJIMA N, KASAMA T, ISOZAKI T et al.: Elevated levels of soluble fractalkine in active systemic lupus erythematosus: Potential involvement in neuropsychiatric manifestations. Arthritis Rheum 2005; 52: 1670-5.
15. FONG AM, ROBINSON LA, STEEBER DA et al.: Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998; 188: 1413-9.
16. CHARO IF, TAUBMAN MB: Chemokines in the pathogenesis of vascular disease. Circ Res 2004; 95: 858-66.
17. CID MC, VILARDELL C: Tissue targeting and disease patterns in systemic vasculitis. Best Pract Res Clin Rheumatol 2001; 15: 259-79.
18. BACON PA: Endothelial cell dysfunction in systeNic vasculitis: new developments and therapeutic prospects. Curr Opin Rheumatol 2005; 17: 49-55.
19. CHEN S, BACON KB, LI L et al.: In vivo inhibition of CC and CX3C chemokine-induced leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II. J Exp Med 1998; 188: 193-8.
20. CHAPMAN GA, MOORES KE, GOHIL J et al.: The role of fractalkine in the recruitment of monocytes to the endothelium. Eur J Pharmacol 2000; 392: 189-95.
21. FURUICHI K, WADA T, IWATA Y et al.: Upregulation of fractalkine in human crescentic glomerulonephritis. Nephron 2001; 87: 314-20.
22. 3C chemokine fractalkine in pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 1419-25.
23. UMEHARA H, BLOOM ET, OKAZAKI T, NAGANO, Y, YOSHIE O, IMAI T: Fractalkine in vascular biology: From basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24: 34-40.
24. RUTH JH, VOLIN MV, HAINES GK 3RD et al.: Fractalkine, a novel chemokine in rheumatoid arthritis and in rat adjuvant-induced arthritis. Arthritis Rheum 2001; 44: 1568-81.
25. BLASCHKE S, KOZIOLEK M, SCHWARZ A et al.: Proinflammatory role of fractalkine (CX3CL1) in rheumatoid arthritis. J Rheumatol 2003; 30: 1918-27.
26. HASEGAWA M, SATO S, ECHIGO T, HAMAGUCHI Y, YASUI M, TAKEHARA K: Up regulated expression of fractalkine/CX3CL1 and CX3CR1 in patients with systemic sclerosis. Ann Rheum Dis 2005; 64: 21-8.
27. BJERKELI V, DAMAS JK, FEVANG B, HOLTER JC, AUKRUST P, FROLAND SS: Increased expression of fractalkine (CX3CL1) and its receptor, CX3CR1, in Wegener's granulomatosis possible role in vascular inflammation. Rheumatology (Oxford) 2007; 46: 1422-7.
28. HERGESELL O, ANDRASSY K, NAWROTH P: Elevated levels of markers of endothelial cell damage and markers of activated coagulation in patients with systemic necrotizing vasculitis. Thromb Haemost 1996; 75: 892-8.
29. AHN SY, CHO CH, PARK KG et al.: Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-alpha-induced fractalkine expression. Am J Pathol 2004; 164: 1663-72.
30. KURYLISZYN-MOSKAL A: Cytokines and soluble CD4 and CD8 molecules in rheumatoid arthritis: Relationship to systematic vasculitis and microvascular capillaroscopic abnormalities. Clin Rheumatol 1998; 17: 489-95.
31. FELDMANN M, PUSEY CD: Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. J Am Soc Nephrol 2006; 17: 1243-52.
32. FOUSSAT A, COULOMB-L'HERMINE A, GOSLING J et al.: Fractalkine receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur J Immunol 2000; 30: 87-97.
33. RUTH JH, ROTTMAN JB, KATSCHKE KJ JR. et al.: Selective lymphocyte chemokine receptor expression in the rheumatoid joint. Arthritis Rheum 2001; 44: 2750-60.